Search hospitals > North Carolina > Durham
Duke Comprehensive Cancer Center
Claim this profileDurham, North Carolina 27705
Global Leader in Brain Tumor
Global Leader in Leukemia
Conducts research for Breast Cancer
Conducts research for Nervous System Tumors
Conducts research for Cancer
625 reported clinical trials
34 medical researchers
Summary
Duke Comprehensive Cancer Center is a medical facility located in Durham, North Carolina. This center is recognized for care of Brain Tumor, Leukemia, Breast Cancer, Nervous System Tumors, Cancer and other specialties. Duke Comprehensive Cancer Center is involved with conducting 625 clinical trials across 320 conditions. There are 34 research doctors associated with this hospital, such as Angeles A. Secord, Harry P. Erba, Richard Riedel, MD, and Mustafa Khasraw, M.D..Area of expertise
1Brain Tumor
Global LeaderStage IV
Stage III
IDH positive
2Leukemia
Global LeaderPhiladelphia chromosome
NPM1-m positive
B-cell
Top PIs
Angeles A. SecordDuke University Medical Center3 years of reported clinical research
Studies Ovarian Cancer
Studies Fallopian Tube Cancer
16 reported clinical trials
30 drugs studied
Harry P. ErbaDuke University Medical Center5 years of reported clinical research
Expert in Leukemia
Studies Acute Myeloid Leukemia
14 reported clinical trials
26 drugs studied
Richard Riedel, MDDuke University Medical Center4 years of reported clinical research
Studies Sarcoma
Studies Soft Tissue Sarcoma
11 reported clinical trials
18 drugs studied
Mustafa Khasraw, M.D.Duke University Medical Center4 years of reported clinical research
Studies Brain Tumor
Studies Glioblastoma
10 reported clinical trials
15 drugs studied
Clinical Trials running at Duke Comprehensive Cancer Center
Breast Cancer
Colorectal Cancer
Solid Tumors
Cancer
Melanoma
Non-Small Cell Lung Cancer
Endometrial Cancer
Tumors
Squamous Cell Carcinoma
Prostate Cancer
Sacituzumab Govitecan + Pembrolizumab
for Triple Negative Breast Cancer
The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which includes either pembrolizumab or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after surgery and pre-surgical treatment.
Recruiting2 awards Phase 36 criteria
Abemaciclib + Elacestrant
for Breast Cancer with Brain Metastasis
This is a multi-institutional, single arm, open label, Phase Ib/II study of abemaciclib in combination with elacestrant in patients with HR+/Her2- breast cancer metastatic to the brain. Patients may have received up to two prior lines of systemic chemotherapy for locally advanced or metastatic disease. There will be no limit on prior use of endocrine therapy including aromatase inhibitors, tamoxifen and fulvestrant, given a documented clinical benefit of elacestrant in this setting.
Recruiting1 award Phase 1 & 212 criteria
Hormone Therapy
for Cardiovascular Health in Breast Cancer Patients
The purpose of this research study is to understand what effect near complete estrogen deprivation (NCED) therapy has on the heart in breast cancer patients. Investigators want to understand if NCED changes how the heart works.
Recruiting1 award Phase < 111 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Duke Comprehensive Cancer Center?
Duke Comprehensive Cancer Center is a medical facility located in Durham, North Carolina. This center is recognized for care of Brain Tumor, Leukemia, Breast Cancer, Nervous System Tumors, Cancer and other specialties. Duke Comprehensive Cancer Center is involved with conducting 625 clinical trials across 320 conditions. There are 34 research doctors associated with this hospital, such as Angeles A. Secord, Harry P. Erba, Richard Riedel, MD, and Mustafa Khasraw, M.D..
Where is Duke Comprehensive Cancer Center located?
To reach the Duke Comprehensive Cancer Center in Durham, NC:
- Take the 147 Durham Freeway Exit (Exit 279 B) from I-40, then the Elba Street/Trent Drive Exit (Exit 15 A).
- Enter the left lane and turn left into the Parking Deck on your left before the next light.
- For accessible transportation, use the Duke Van Service by calling 919.684.2020.
Who should I call to ask about financial aid or insurance network?
For insurance-related inquiries at Duke Comprehensive Cancer Center, contact DCU Insurance at 508.263.6978, email insurance@dcu.org, or fax 866.897.2629. For financial assistance, reach out to the Financial Relief Program at 800-723-2210. For debt and budget management, contact BALANCE at 888.456.2227.
What insurance does Duke Comprehensive Cancer Center accept?
The Duke Comprehensive Cancer Center accepts a variety of insurance plans, including commercial health insurance plans (Aetna, Blue Cross Blue Shield of North Carolina, CIGNA Healthcare of NC, Humana, Optima Health, Progyny, United Healthcare) with HMO, POS, and PPO options. Coverage extends to pharmacy and behavioral health benefits. The center also accepts exchange health insurance plans from Healthcare.gov, Medicare Advantage Plans, and Medicaid Managed Care.
What awards or recognition has Duke Comprehensive Cancer Center received?
The Duke Comprehensive Cancer Center in Durham, North Carolina, is renowned for its significant research funding and groundbreaking studies. It has received a $6,693 award from 5 for the Fight for "Dr. Anders-Cancer Research" and a $1,932,000 award from the Department of Defense for "DoD: PCRP Clinical Consortium: Duke University Clinical Research Site". The center is also recognized for its research into racial differences in breast cancer outcomes, highlighting the disparity in chemotherapy response between Black and white women for triple negative breast cancer.